Shire pledges $260M-plus in deal for liver-focused Lumena

Lumena won't be going through with that $75 million IPO after all. Shire is scooping up the company and its two development programs for rare liver diseases for $260 million in cash along with an undisclosed slate of milestones. The deal comes as analysts buzz about whether Shire ($SHPG) itself may be targeted for an acquisition by either AstraZeneca ($AZN) or Allergan ($AGN), which are both trying to wrestle out of the grip of an unwelcome buyout offer. Report